Aggressive Non-Hodgkin Lymphoma

Known as: Aggressive Non-Hodgkin's Lymphoma, Non-Hodgkin lymphoma, aggressive, NOS, aggressive lymphoma 
A non-Hodgkin lymphoma with an aggressive clinical course. Representative examples include Burkitt lymphoma, mantle cell lymphoma, and… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
PURPOSE To investigate the incidence, natural history, and risk factors predictive of CNS relapse in patients with de novo… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE The major cause of death in aggressive lymphoma is relapse or nonresponse to initial therapy. Lenalidomide has activity… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND Chemoradiotherapy is standard treatment for localized aggressive lymphoma. To determine the optimal therapy for… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Assessment of early therapeutic response using metabolic imaging is potentially useful to determine prognosis in aggressive… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
PURPOSE To compare low-dose (30 Gy) radiotherapy (RT) with observation (OBS) in limited-stage aggressive lymphoma patients… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Cyclophosphamide, doxorubicin, vincristine, and prednisone, given every 3 weeks (CHOP-21), is standard chemotherapy for… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
The combination of cyclophosphamide, doxorubicin, vincristine, and prednisone, given every 3 weeks (CHOP-21) is standard… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2003
Highly Cited
2003
We conducted a randomized trial to compare the intensive conventional chemotherapy regimen ACVBP (doxorubicin, cyclophosphamide… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 4
Is this relevant?
2003
2003
This study was designed to determine the value of 2-[fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2002
Highly Cited
2002
UNLABELLED Early identification of chemotherapy-refractory lymphoma patients provides a basis for alternative treatment… (More)
Is this relevant?